Why the study?
Does decreased renal function increase coagulation and fibrinolysis markers in patients with non-valvular atrial fibrillation?
Does decreased renal function increase coagulation and fibrinolysis markers in patients with non-valvular atrial fibrillation?
Decreased renal function is associated with enhanced coagulation activation in patients with non-valvular atrial fibrillation, suggesting it may serve as a predictor for thromboembolic events.
Decreased eGFR was associated with coagulation activation in non-valvular AF; leaves open its value for thromboembolic prediction pending prospective validation.
BACKGROUND: The prothrombotic state in non-valvular atrial fibrillation (NVAF) increases the risk of thromboembolic events. It is also well known that a prothrombotic state exists in renal failure. Hemostatic disorders play a role in thromboembolic mortality in both NVAF and renal failure. However, little is known about the influence of renal function on hemostasis in patients with NVAF. METHODS AND RESULTS: A total of 190 consecutive outpatients with NVAF who were not receiving anticoagulant therapy were enrolled in the present study. Patients were stratified in groups based on estimated glomerular filtration rate (eGFR). Plasma concentrations of thrombin-antithrombin complex (TAT) and D-dimer were measured and the influence of renal function on coagulation and fibrinolysis was assessed. A relatively weak and inverse relationship of eGFR to TAT and D-dimer was observed (r=0.28, P=0.0001; r=0.30, P<0.0001). Both mean TAT and D-dimer concentrations in groups gradually and significantly increased as eGFR decreased (P<0.0001). On multivariate regression analysis, decreased eGFR concentration was a significant predictor for elevation of TAT (P<0.05) and D-dimer (P<0.01) in patients with NVAF. CONCLUSIONS: The enhanced coagulation activation appeared to be related to a reduction in residual renal function in patients with NVAF. This suggests that decreased renal function might be a candidate predictor of thromboembolic events in patients with NVAF.
No takes yet. Share an insight, caveat, or question.
Tanaka et al. (2009) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: